Seeking Alpha

Shares of BioCryst Pharmaceuticals (BCRX +3.4%) get a lift after the company reveals its BCX4208...

Shares of BioCryst Pharmaceuticals (BCRX +3.4%) get a lift after the company reveals its BCX4208 gout drug met its primary endpoint in a Phase 2b randomized, double-blind, dose-response study. CEO Jon Stonehouse says the next big step is to find a partner for lead development for the drug that he says has a market potential of $500M.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs